Rocket Lab: A $2.2 Billion Backlog Meets a $67 Million Insider Exit as Earnings Approach
10.06.2026 - 18:45:48 | boerse-global.de
Rocket Lab’s stock has enjoyed a breathless 296% climb over the past year, but the recent weeks have told a more cautious story. With the company trading 29% below its all-time high of $151.00, a wave of insider profit-taking and bearish options positioning has cast a shadow over an otherwise robust order book. The next major test arrives on August 5, when the second-quarter results are due — a moment that will test whether operational momentum can keep the valuation aloft.
The order book itself has never looked stronger. Rocket Lab recently pushed its backlog to a record $2.2 billion, anchored by a multi-year block-buy agreement that secures launch slots for five Neutron and three Electron rockets through 2029. A $190 million contract with the US military for 20 hypersonic test flights using the HASTE variant of Electron adds further heft. Combined, the launch manifest now covers more than 70 missions. Yet the backlog’s composition tells its own story: only 41.5% comes from launch services, with satellite components and full spacecraft manufacturing making up the rest. The company has transformed from a pure-play rocket operator into an integrated space concern.
That transformation has not insulated the stock from skepticism. Over the past 90 days, insiders have sold roughly $67 million worth of shares, with the chief financial officer and a vice-president dumping their stakes near the May peak. The selling coincides with a marked shift in the options market. The put-call ratio has climbed to 0.69, well above the typical level of 0.52, and implied volatility has hit its highest reading of the last twelve months. Short sellers are also active, holding about 32 million shares — roughly 6% of the free float. A brief bout of geopolitical nerves, sparked by an incident involving a US military helicopter over the Strait of Hormuz, added to the pressure on aerospace names on Tuesday, sending Rocket Lab shares to $108.23.
Should investors sell immediately? Or is it worth buying Rocket Lab USA?
The financials help explain the caution. Revenue surged 63% year-over-year in the first quarter to around $200 million, but the company remained in the red with a loss of $0.07 per share. Analysts have responded with a tempered outlook: the average price target stands at roughly $99, implying further downside from current levels. The valuation, by any measure, is stretched relative to the earnings base.
What could reignite confidence is the Neutron rocket. Management has confirmed the first flight is set for the fourth quarter of 2026, a delay driven by design changes to the tank structure and testing at the Wallops facility. Neutron is designed to lift 13 tonnes to orbit using reusable carbon-composite airframes, and a successful debut would make Rocket Lab the only US provider in the medium-lift segment alongside the established heavyweights. That prospect is the fundamental reason many investors are willing to look past the near-term consolidation.
For now, the stock sits at $107.54, with a relative strength index of 45.4 indicating neutral conditions. The 296% annual gain is a powerful testament to Rocket Lab’s trajectory, but the insider exits, elevated short interest, and a pending earnings report are reminders that even the most promising space stories must answer to quarterly realities.
Ad
Rocket Lab USA Stock: New Analysis - 10 June
Fresh Rocket Lab USA information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
